Bare Financial Services’s Lexeo Therapeutics LXEO Stock Holding History

Bare Financial Services’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-80	Closed	-$459	–	1856
2026 Q1	$459	Buy	+80	New	+$567	﹤0.01%	1602

Other funds holding LXEO

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Bare Financial Services's LXEO Position: Q2 2026 in Review

Bare Financial Services sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 80 shares — an estimated $459 sold.

Bare Financial Services first reported a position in LXEO in Q1 2026 and held it in 1 quarter. The position peaked at $459 in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Bare Financial Services reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
Bare Financial Services sold 80 Lexeo Therapeutics shares in Q2 2026, an estimated $459.
Bare Financial Services first reported a position in Lexeo Therapeutics in Q1 2026 and held it in 1 quarter.
Bare Financial Services's Lexeo Therapeutics position peaked at $459 in Q1 2026.
142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.